Cargando…

Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients

Current data demonstrated that in patients with coronavirus disease-19 (COVID-19), there is a dysregulation of the immune system during the severe form of the disease. This dysregulation is expressed with an uncontrolled release of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, IL-17...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelechas, Eleftherios, Drossou, Vassiliki, Voulgari, Paraskevi V., Drosos, Alexandros A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Mediterranean Journal of Rheumatology (MJR) 2022
Materias:	Case-Based Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092100/ https://www.ncbi.nlm.nih.gov/pubmed/35611100 http://dx.doi.org/10.31138/mjr.33.1.68

Ejemplares similares

Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?
por: Pelechas, Eleftherios, et al.
Publicado: (2020)

COVID-19 in patients with gout on colchicine
por: Pelechas, Eleftherios, et al.
Publicado: (2021)

A not-to-miss Cause of Severe Cervical Spine Pain in a Patient with Rheumatoid Arthritis: A Case-Based Review
por: Drosos, Alexandros A., et al.
Publicado: (2021)

Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience
por: Migkos, Michalis P., et al.
Publicado: (2021)

Colchicine Against SARS-CoV-2 Infection: What is the Evidence?
por: Drosos, Alexandros A., et al.
Publicado: (2022)

A Response to: Letter to the Editor Regarding the Article: “Colchicine Against SARS-CoV-2 Infection: What is the Evidence?”
por: Drosos, Alexandros A., et al.
Publicado: (2022)

Golimumab for Rheumatoid Arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?
por: Drosos, Alexandros A., et al.
Publicado: (2019)

Seronegative Erosive Arthritis Following SARS-CoV-2 Infection
por: Drosos, Alexandros A., et al.
Publicado: (2021)

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
por: Pelechas, Eleftherios, et al.
Publicado: (2017)

Long COVID from rheumatology perspective: a simple mimicker or promoter of autoimmunity?
por: Drosos, Alexandros A., et al.
Publicado: (2022)

A Patient with Symmetrical Polyarthritis. The Value of Conventional Radiography for a Correct Diagnosis
por: Drosos, Alexandros A., et al.
Publicado: (2022)

Treatment strategies of COVID-19: A rheumatology perspective
por: Drosos, Alexandros A., et al.
Publicado: (2022)

Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative Open-Label Study
por: Kaltsonoudis, Evripidis, et al.
Publicado: (2019)

An uncommon presentation of Granulomatosis with Polyangiitis
por: Pelechas, Eleftherios, et al.
Publicado: (2018)

Comment on the Article “Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature”
por: Drosos, Alexandros A., et al.
Publicado: (2023)

Biologic Therapies and Autoimmune Phenomena
por: Drosos, Alexandros A., et al.
Publicado: (2021)

Long-term use of adalimumab in the treatment of rheumatic diseases
por: Papagoras, Charalampos, et al.
Publicado: (2009)

The usefulness of magnetic resonance imaging of the hand and wrist in very early rheumatoid arthritis
por: Kosta, Paraskevi E, et al.
Publicado: (2011)

The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital
por: Kaltsonoudis, Evripidis, et al.
Publicado: (2019)

Fasting mimicking diets: A literature review of their impact on inflammatory arthritis
por: Venetsanopoulou, Aliki I., et al.
Publicado: (2019)

Dermatomyositis sine myositis – Case presentation
por: Kaltsonoudis, Evripidis, et al.
Publicado: (2017)

Periodontal Condition in Patients with Rheumatoid Arthritis: Effect of Anti-rheumatic Drugs
por: Kordtabar, Samira, et al.
Publicado: (2019)

Effect of Anti-Rheumatic Drugs on Cardiovascular Disease Events in Rheumatoid Arthritis
por: Baoqi, Yang, et al.
Publicado: (2022)

Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry
por: Papadopoulos, Christos G, et al.
Publicado: (2019)

Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study
por: Panopoulos, Stylianos, et al.
Publicado: (2018)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
por: Giachi, Andrea, et al.
Publicado: (2022)

Gout, Rheumatism, and Rheumatoid Arthritis
Publicado: (1900)

Chronic Rheumatism and Rheumatoid Arthritis
por: Lindsay, J.
Publicado: (1908)

Anti-inflammatory activity of nicotine isolated from Brassica oleracea in rheumatoid arthritis
por: Rakhecha, Bharti, et al.
Publicado: (2022)

Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study
por: Kaltsonoudis, Evripidis, et al.
Publicado: (2014)

Favorable retention rates and safety of conventional anti-rheumatic drugs in older patients with rheumatoid arthritis
por: Alpay-Kanitez, Nilüfer, et al.
Publicado: (2020)

Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
por: Choy, Ernest H
Publicado: (2019)

Exploring the treatment burden of disease-modifying anti-rheumatic drug monitoring in people with rheumatoid arthritis
por: Ryan, Sarah, et al.
Publicado: (2023)

Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis
por: Su, Yu-Jih, et al.
Publicado: (2023)

Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin
por: Venetsanopoulou, Aliki I., et al.
Publicado: (2020)

Sulfasalazine induced immune thrombocytopenia in a patient with rheumatoid arthritis
por: Narayan, Nehal, et al.
Publicado: (2016)

Rheumatoid arthritis with pachymeningitis – a case presentation and review of the literature
por: Joshi, Sanyukta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1jdhffi3dn3t2qrpqp9654rorh